Skip to content
Owl Posting cover art

Abhishaike Mahajan

Owl Posting

A Nature and Science podcast

Good podcast? Give it some love!

About the show

a podcast about the intersection of biology and computation. all episodes on https://www.owlposting.com/s/podcast! www.owlposting.com

Newest episodes

How to design a cancer vaccine (and vastly improve them): Alex Rubinsteyn & Ben Vincent

2 hr 59 min

Spotify: https://open.spotify.com/episode/5xk4OjH1jVYbDR6xTTvqCY?si=11564348b75a459a Apple Podcasts: https://podcasts.apple.com/us/podcast/owl-posting/id1758545538?i=1000775598448 Youtube: https://youtu.be/EmbciAO9d-M Transcript: https://www.owlposting.com/p/how-to-design-a-cancer-vaccine-and?open=false#%C2%A7transcript Back in early May, I flew to North Carolina to interview Alex Rubinsteyn (left) and Benjamin Vincent (right). Together, they run the Personalized Immunotherapy Research Lab (PIRL) at UNC-Chapel Hill. It would be difficult for me to emphasize the degree to which Alex and Benjamin are in a league of their own amongst almost any other researcher I have ever met, demonstrating a degree of translational ambition, scientific insight, clarity of thought, and just genuine kindness that one rarely sees. And each time I stumble across a person like this, I try my best to get them in front of a camera. This is the first interview I’ve ever done where I traveled specifically for a guest(s), and I’m very, very glad I did it. We’re in an interesting moment with cancer vaccines. Between Sid Sijbrandij’s ‘founder mode’ journey on his cancer (which involved cancer vaccines), and the dog cancer vaccine story, a lot of eyes are being directed here. As luck would have it, Alex and Benjamin have spent a fairly high fraction of their career in this exact field, and have contributed to some of the most foundation work in it: MHCflurry 2.0, OpenVax, LENS, and plenty of other work. In fact, Alex actually helped run a neoantigen cancer vaccine trial a few years back! So obviously, they’d make for great conversation here. We talked for three hours about this area, eventually stretching beyond cancer vaccines and discussing the grander field of personalized immunotherapy. This is comfortably the longest episode I’ve ever recorded, and I suspect we could have gone for an hour longer. Finally: this is a complicated subject, and we really get into the details. Because of it, it ma...

The printing press for biological data (Sterling Hooten)

2 hr 3 min

Youtube: https://youtu.be/-rlJDGC2eC8Apple Podcasts: https://podcasts.apple.com/us/podcast/owl-posting/id1758545538?i=1000762410502Spotify: https://open.spotify.com/episode/1OtuQYwNhRhVSwHiHxPrmV?si=tD52iE5IR8i-3W6Q7Bhy8gSubstack/Transcript: https://www.owlposting.com/p/the-printing-press-for-biological After having written long-form essays over a weirdly diverse number of areas of the life-sciences, I am increasingly confident in my status as someone who knows a little about a lot of things. But every now and then, you meet someone who casually reveals to you an entire subfield who, up until your conversation with them, you’d never even thought of before. This happened to me when I met Sterling a few months back. We met in the elevator as we were both leaving an event, and by the time we’d reached the bottom floor, the conversation had become so interesting that we stood in the lobby for an hour as I pestered him with more and more questions. Sterling runs a company called Iku Bio. Iku ostensibly does something quite simple: it helps biologics manufacturers figure out what to feed their cells. This is called media optimization, and it is done in an astonishingly old-fashioned way. An engineer runs a handful of experiments in a benchtop bioreactor the size of a Fiji water bottle, waits days for analytical results, and repeats, maybe three or four times before timelines force them to stop searching. Sterling’s solution was to use printed circuit boards (PCBs)—the same green wafers inside your phone and your microwave—as the substrate for microfluidic bioreactors. Because PCBs are made via lithography, you get complexity for free. Because they’re already mass-manufactured at planetary scale, you inherit sixty years of cost optimization. And because they’re literally designed to carry electrical signals, you can embed sensors directly into the thing rather than cramming them in after the fact. The result is a device that costs $8 per experimental lane versus $20,000 fo...

Neurotechnology? For Cancer? (Ben Woodington & Elise Jenkins)

1 hr 33 min

Youtube:https://youtu.be/JAxkqb-nBWs Spotify: https://open.spotify.com/episode/6BLZph2uGGUVphbNQ8NGPd?si=SVBSKJM8RdO4AhYzDa-ZfQ Apple Podcast: https://apple.co/3OU5Zse Transcript: https://www.owlposting.com/i/189602943/transcript This is an episode with Ben Woodington and Elise Jenkins, who are the cofounders of Coherence Neuro. The pitch for Coherence is as follows: a brain implant that treats cancer with electricity. When I first learned of the company in mid-2025, it was such an alien thesis that I instinctively wrote it off entirely. This surely isn’t clinically plausible at all, maybe it will be one day, but certainly not today. Then, while I was in San Francisco, I met up with Nicole, Coherence’s chief of staff. After that, I was far more convinced that there was something real here, especially after she told me that the electricity ←→ cancer thesis already has some merit: Optune, an FDA-approved medical device developed by Novocure. This has been on the market for over a decade, and uses externally delivered alternating electric fields to treat glioblastoma. And it works! If Optune is consistently used, glioblastoma patients can live up to twice as long compared to chemotherapy alone. How does it work? Simple: the alternating electrical fields prevent fast-dividing cells from replicating by interfering with the physical process of cell division (specifically, mitotic spindle formation). After this, Nicole connected me with Ben and Elise, the cofounders of the company. It was an incredible conversation. During it, I was informed that cancer cells behave eerily similar to neurons: hijacking neural pathways, attracting nerves into their microenvironment, and forming synaptic connections with surrounding tissue. Given this set of evidence, none of which felt particularly controversial, an easy logical leap is to ask the question: why can’t you throw neuromodulation at the tumor? Maybe not even just for treatment, but monitoring as well? Optune was a step in the...

Similar podcasts

All episodes

How to design a cancer vaccine (and vastly improve them): Alex Rubinsteyn & Ben Vincent

2 hr 59 min

Spotify: https://open.spotify.com/episode/5xk4OjH1jVYbDR6xTTvqCY?si=11564348b75a459a Apple Podcasts: https://podcasts.apple.com/us/podcast/owl-posting/id1758545538?i=1000775598448 Youtube: https://youtu.be/EmbciAO9d-M Transcript: https://www.owlposting.com/p/how-to-design-a-cancer-vaccine-and?open=false#%C2%A7transcript Back in early May, I flew to North Carolina to interview Alex Rubinsteyn (left) and Benjamin Vincent (right). Together, they run the Personalized Immunotherapy Research Lab (PIRL) at UNC-Chapel Hill. It would be difficult for me to emphasize the degree to which Alex and Benjamin are in a league of their own amongst almost any other researcher I have ever met, demonstrating a degree of translational ambition, scientific insight, clarity of thought, and just genuine kindness that one rarely sees. And each time I stumble across a person like this, I try my best to get them in front of a camera. This is the first interview I’ve ever done where I traveled specifically for a guest(s), and I’m very, very glad I did it. We’re in an interesting moment with cancer vaccines. Between Sid Sijbrandij’s ‘founder mode’ journey on his cancer (which involved cancer vaccines), and the dog cancer vaccine story, a lot of eyes are being directed here. As luck would have it, Alex and Benjamin have spent a fairly high fraction of their career in this exact field, and have contributed to some of the most foundation work in it: MHCflurry 2.0, OpenVax, LENS, and plenty of other work. In fact, Alex actually helped run a neoantigen cancer vaccine trial a few years back! So obviously, they’d make for great conversation here. We talked for three hours about this area, eventually stretching beyond cancer vaccines and discussing the grander field of personalized immunotherapy. This is comfortably the longest episode I’ve ever recorded, and I suspect we could have gone for an hour longer. Finally: this is a complicated subject, and we really get into the details. Because of it, it ma...

The printing press for biological data (Sterling Hooten)

2 hr 3 min

Youtube: https://youtu.be/-rlJDGC2eC8Apple Podcasts: https://podcasts.apple.com/us/podcast/owl-posting/id1758545538?i=1000762410502Spotify: https://open.spotify.com/episode/1OtuQYwNhRhVSwHiHxPrmV?si=tD52iE5IR8i-3W6Q7Bhy8gSubstack/Transcript: https://www.owlposting.com/p/the-printing-press-for-biological After having written long-form essays over a weirdly diverse number of areas of the life-sciences, I am increasingly confident in my status as someone who knows a little about a lot of things. But every now and then, you meet someone who casually reveals to you an entire subfield who, up until your conversation with them, you’d never even thought of before. This happened to me when I met Sterling a few months back. We met in the elevator as we were both leaving an event, and by the time we’d reached the bottom floor, the conversation had become so interesting that we stood in the lobby for an hour as I pestered him with more and more questions. Sterling runs a company called Iku Bio. Iku ostensibly does something quite simple: it helps biologics manufacturers figure out what to feed their cells. This is called media optimization, and it is done in an astonishingly old-fashioned way. An engineer runs a handful of experiments in a benchtop bioreactor the size of a Fiji water bottle, waits days for analytical results, and repeats, maybe three or four times before timelines force them to stop searching. Sterling’s solution was to use printed circuit boards (PCBs)—the same green wafers inside your phone and your microwave—as the substrate for microfluidic bioreactors. Because PCBs are made via lithography, you get complexity for free. Because they’re already mass-manufactured at planetary scale, you inherit sixty years of cost optimization. And because they’re literally designed to carry electrical signals, you can embed sensors directly into the thing rather than cramming them in after the fact. The result is a device that costs $8 per experimental lane versus $20,000 fo...

Neurotechnology? For Cancer? (Ben Woodington & Elise Jenkins)

1 hr 33 min

Youtube:https://youtu.be/JAxkqb-nBWs Spotify: https://open.spotify.com/episode/6BLZph2uGGUVphbNQ8NGPd?si=SVBSKJM8RdO4AhYzDa-ZfQ Apple Podcast: https://apple.co/3OU5Zse Transcript: https://www.owlposting.com/i/189602943/transcript This is an episode with Ben Woodington and Elise Jenkins, who are the cofounders of Coherence Neuro. The pitch for Coherence is as follows: a brain implant that treats cancer with electricity. When I first learned of the company in mid-2025, it was such an alien thesis that I instinctively wrote it off entirely. This surely isn’t clinically plausible at all, maybe it will be one day, but certainly not today. Then, while I was in San Francisco, I met up with Nicole, Coherence’s chief of staff. After that, I was far more convinced that there was something real here, especially after she told me that the electricity ←→ cancer thesis already has some merit: Optune, an FDA-approved medical device developed by Novocure. This has been on the market for over a decade, and uses externally delivered alternating electric fields to treat glioblastoma. And it works! If Optune is consistently used, glioblastoma patients can live up to twice as long compared to chemotherapy alone. How does it work? Simple: the alternating electrical fields prevent fast-dividing cells from replicating by interfering with the physical process of cell division (specifically, mitotic spindle formation). After this, Nicole connected me with Ben and Elise, the cofounders of the company. It was an incredible conversation. During it, I was informed that cancer cells behave eerily similar to neurons: hijacking neural pathways, attracting nerves into their microenvironment, and forming synaptic connections with surrounding tissue. Given this set of evidence, none of which felt particularly controversial, an easy logical leap is to ask the question: why can’t you throw neuromodulation at the tumor? Maybe not even just for treatment, but monitoring as well? Optune was a step in the...

What if we could grow human tissue by recapitulating embryogenesis? (Matthew Osman & Fabio Boniolo)

2 hr 1 min

This is an interview with Matthew Osman and Fabio Boniolo, the co-founders of Polyphron. The thesis behind Polyphron is equal parts nauseating and exciting in how ambitious it is: growing ex-vivo tissue to use in organ repair. And, truthfully, it felt so ambitious as to not be possible at all. When I had my first (of several) pre-podcast chats with Matt and Fabio to understand what they were doing, I expressed every ounce of skepticism I had about how this couldn’t possibly be viable. Everybody knows that complex tissue engineering is something akin to how fusion is viewed in physics; theoretically possible, but practically intractable in the near-term. What we can reliably grow outside of a human body are simple structures—bones, skin, cartilage—but anything beyond that is surely decades away. But after the hours of conversation I’ve had with the team, I’ve began to rethink my position. As Eryney Marrogi lines out in his Core Memory article over Polyphron (https://www.corememory.com/p/exclusive-cracking-the-only-engineering), there is an engineering system that has reliably produced viable human tissue for eons: embryogenesis. What if you could recapitulate this process? What if you could naturally get cells to arrange themselves into higher-order structures, by following the exact chemical guidelines that are laid out during embryo development? And, most excitedly, what if you didn’t need to understand any of these overwhelmingly complex development rules, but could outsource it all to a machine-learning system that understood what set of chemical perturbations are necessary at which timepoints? This does not exist today, but Polyphron has given early proof points that is possible. In their most recent finding, which we talk about on the podcast, their models have discovered a distinct set of chemical perturbations that force developing neurons to arrange themselves with a specific polarity: just shy of 90°, arranged like columns. This is obviously still a si...

We don't know what most microbial genes do. Can genomic language models help? (Yunha Hwang, Ep #7)

1 hr 42 min

Note: Thank you to rush.cloud and latch.bio for sponsoring this episode! Rush is augmenting drug discovery for all scientists with machine-driven superintelligence. LatchBio is building agentic scientific tooling that can analyze a wide range of scientific data, with an early focus on spatial biology. Clip on them in the episode. If you’re at all interested in sponsoring future episodes, reach out! *** This is an interview with Yunha Hwang, an assistant professor at MIT (and co-founder of the non-profit Tatta Bio). She is working on building and applying genomic language models to help annotate the function of the (mostly unknown) universe of microbial genomes. There are two reasons you should watch this episode. One, Yunha is working on an absurdly difficult and interesting problem: microbial genome function annotation. Even for E. coli, one of the most studied organisms on Earth, we don’t know what half to two-thirds of its genes actually do. For a random microbe from soil, that number jumps to 80-90%. Her lab is one of the leading groups working to apply deep learning to solving the problem, and last year, released a paper that increasingly feels foundational within it (with prior Owl Posting podcast guest Sergey Ovchinnikov an author on it!). We talk about that paper, its implications, and where the future of machine learning in metagenomics may go. And two, I was especially excited to film this so I could help bring some light to a platform that she and her team at Tatta Bio has developed: SeqHub. There’s been a lot of discussion online about AI co-scientists in the biology space, but I have increasingly felt a vague suspicion that people are trying to be too broad with them. It feels like the value of these tools are not with general scientific reasoning, but rather from deep integration with how a specific domain of research engages with their open problems. SeqHub feels like one of the few systems that mirrors this viewpoint, and while it isn’t something I...

Bringing organ-scale cryopreservation into existence (Hunter Davis, Ep #6)

1 hr 54 min

Sponsor note: the supporter of this video is rush.cloud. If you are at all involved with doing preclinical drug discovery and would benefit from computational tools, you should check out their platform + beautiful website here: rush.cloud. If you’re at all interested in working together for future episodes, reach out! This is an interview with Hunter Davis, the CSO and co-founder (alongside Laura Deming) of Until Labs, which you may also know by its prior name, Cradle. They are a biotech startup devoted to organ-scale cryopreservation. They raised a $58M Series A back in September 2025, and are backed by Founders Fund (especially interesting!), Lux Ventures, and others. In this interview, we mainly talk about the engineering and scientific difficulties in the cryopreservation field, including some background details on their September 2024 progress report on neural slice rewarming, how they characterize tissue damage in their attempts to do kidney cryopreservation, the potential economics of future cryopreservation protocols, and lots more. One of the most interesting conversations I’ve had in a long time. If any of this work seems interesting, Until Labs is actively and aggressively hiring! Enjoy! Substack + Transcript: https://www.owlposting.com/p/bringing-organ-scale-cryopreservation Spotify: https://open.spotify.com/episode/23g2lR7dWl8NXUn893KMgv?si=5628cd0e56184130 Apple Podcasts: https://podcasts.apple.com/us/podcast/bringing-organ-scale-cryopreservation-into-existence/id1758545538?i=1000738128994 Youtube: https://youtu.be/xaqwPd3ujHg Timestamps: [00:01:50] Introduction [00:05:00] Why don’t we have reversible cryopreservation today? [00:07:05] Why is freezing necessary at all for preservation? [00:08:23] Let’s discuss cryoprotectant agents [00:14:09] Until Lab’s 2024 progress report on neural tissue cryopreservation [00:20:28] How do you measure cryopreserved tissue damage? [00:22:34] Translation across species [00:26:04] Why was the cryopreservation storage t...

Can machine learning enable 100-plex cryo-EM structure determination? (Ellen Zhong, Ep #5)

1 hr 40 min

Sponsor note: I am extremely happy to announce my first commercial, service-oriented sponsor: rush.cloud. I’ve been doing these podcasts entirely through very kind philanthropic graces, which is very nice, but I’d ideally like to be helping someone when they sponsor me. And now I have that! So, if you are at all involved doing preclinical drug discovery and would benefit from computational tools, you should check out their platform + beautiful website here: rush.cloud. ****** Youtube: https://www.youtube.com/watch?v=W0m3Ltz_YqU Apple Podcasts: https://podcasts.apple.com/us/podcast/owl-posting/id1758545538?i=1000736122646 Spotify: https://open.spotify.com/episode/5l9RMbMwdgOrrZ6uLS656R?si=938af7d2b79440a1 Transcript: https://www.owlposting.com/p/can-machine-learning-enable-100-plex?open=false#%C2%A7transcript ****** Introduction: Ellen Zhong is perhaps one of the only people in the ML x bio field to have created an entirely new subfield of research during her PhD: the application of deep-learning to cryo-EM particle images. If you aren’t familiar with that field, I luckily have a 8,000~ word article covering it, which walks through a lot of Ellen’s papers. If you don’t have time to read something that grossly large, the general breakdown of the problem is as follows: cryo-EM can give you thousands of 2D views of a 3D protein from many different angles, from that data, can you discover what that 3D structure is? Ellen, who is a computer science professor at Princeton University, has spent her academic career investigating that question, and now has an entire lab at Princeton (E.Z. Lab) focused on that and related ones. Including, as the title mentions, the possibility of doing performing cryo-EM structure determination at ultra-high scales. In this podcast, we talk about her research, what she did during her recent sabbatical at Generate:Biomedicines, her recent interest in areas beyond cryo-EM (cryo-ET and NMR specifically), and more! Timestamps [00:00:00] Introducti...

The DNA protection company (Alan Tomusiak, Ep #4)

1 hr 43 min

Note: Extremely grateful for Geltor (http://geltor.com/) for sponsoring this podcast, and for the founder of it (https://www.linkedin.com/in/alexanderlorestani) for reaching out to make to start with! Geltor produces designer proteins for beauty and wellness. The current in-vogue thing to do for most longevity companies is to go for cellular reprogramming. As in, fill a cell with the right transcription factors needed to reduce epigenetic noise, restore mitochondrial dysfunction, and so on. I’ve written about the promise there before, it’s definitely an exciting field. So, when I first met Alan— who told me that he was a longevity researcher — last October, I naively assumed he was also on the reprogramming train. But he told me that he was investigating something a bit different. His pitch was that, instead of reprogramming the cell to fix age-related damage, what if you just protected it from (genetic) insult first? It’s an obvious idea, but one that I’d never really deeply considered. He sold me on the concept, and I was very curious to hear what he’d do next to push it forwards. A few months after our chat, he spun up a company to pursue this line of thinking: Permanence Bio, which develops molecules that stabilize/protect the genome. They are just about eight months old, but there are already some exciting results coming out. I’m a sucker for people doing ‘contrarian research in consensus fields’, and I immediately knew I wanted to have Alan on the podcast. He graciously agreed and, during my trip to SF last month, we sat down and talked for a few hours. In this episode, we talk about why DNA protection is so important, what indications is it useful for, how to mentally conceptualize the idea of a molecule ‘stabilizing’ a genome, what it was like to raise money for a company pursuing such an out-of-distribution thesis, and lots more. Finally, Alan has a really great blog (something I mention in the video), and I wanted to attach a much longer article he’s writt...

What could Alphafold 4 look like? (Sergey Ovchinnikov, Ep #3)

2 hr 6 min

X: https://x.com/owl_posting Sergey's X: https://x.com/sokrypton Youtube: https://youtu.be/6_RFXNxy62c Spotify: https://open.spotify.com/episode/0wPs3rmp0zrfauqToozrcv?si=DCtRf-xQTPiVYwslo-b2rQ Apple Podcasts: https://podcasts.apple.com/us/podcast/what-could-alphafold-4-look-like-sergey-ovchinnikov-3/id1758545538?i=1000704927828 Transcript: https://www.owlposting.com/p/what-could-alphafold-4-look-like?open=false#%C2%A7transcript To those in the protein design space, Dr. Sergey Ovchinnikov is a very, very well-recognized name. A recent MIT professor (circa early 2024), he has played a part in a staggering number of recent innovations in the field: ColabFold, RFDiffusion, Bindcraft, automated design of soluble proxies of membrane proteins, elucidating what protein language models are learning, conformational sampling via Alphafold2, and many more. Of course, all these papers were group efforts, but Sergey's name comes up astonishingly frequently! And even beyond the research that have come from his lab in the last few years, the co-evolution work he did during his PhD/fellowship also laid some of the groundwork for the original Alphafold paper, being cited twice in it. As a result, Sergey’s work has gained a reputation for being something that is worth reading. But nobody has ever interviewed him before! Which was shocking for someone who was so pivotally important for the field. So, obviously, I wanted to be the first one to do it. After an initial call, I took a train down to Boston, booked a studio, and chatted with him for a few hours, asking every question I could think of. We talk about his own journey into biology research, some issues he has with Alphafold3, what Alphafold4-and-beyond models may look like, what research he’d want to spend a hundred million dollars on, and lots more. Take a look at the timestamps to get an overview! Final note: I’m extremely grateful to Asimov Press for helping fund the travel + studio time required for this episode! They are a...

How do you make a 250x better vaccine at 1/10 the cost? Develop it in India. (Soham Sankaran, Ep #2)

2 hr 15 min

This is an interview with Soham Sankaran, the founder and CEO of PopVax, an mRNA vaccine development startup. Curiously, PopVax is based in India, specifically Hyderabad. This should be a surprise to most people in the field: we never really hear of interesting biotech research being done in a place that isn’t [US, Europe, East Asia]. Yet, PopVax has been astonishingly successful, having a (in mouse) influenza vaccine that is 250x better than its competitors, multiple large research collaborations, and their first upcoming US based phase 1 clinical trial being fully sponsored and conducted by the NIH. It’s an extremely interesting success story from what feels like a very clear underdog. In this 2-hour podcast, we discuss everything from why so little biotech research gets done in India, a breakdown on what you care about in vaccine design (immunogens), how PopVax uses machine learning for precise immunogen design, how raising money for a vaccinology startup is going, and a lot more. Timestamps and transcripts are below. Just as in my last episode, I’ve included a ‘jargon explanation’ as a quick primer for some of the subjects discussed in the episode. Some final bits: the studio rental costs were kindly covered by Dylan Reid! Huge shout-out to him for making this episode possible. Also shout-out to Samarth Jajoo, Reha Mathur, and David Yang for some very helpful discussion about the Indian biotech scene. And, if you think PopVax is interesting, here is their Substack which has some articles on their results, their job section (they are actively hiring), and can be reached at contact@popvax.com. Timestamps 01:31 Introduction 02:38 Why is there such little biotech research in India? 17:43 Advantages of building a company in India 31:30 Policy prescriptions for India 35:39 Questions on vaccine design 50:55 What does PopVax do? 01:01:58 The role of machine learning in vaccine design 01:12:07 The (conservative) culture of vaccinology 01:26:57 Hiring in India 01:46:52 H...

Can AI improve the current state of molecular simulation? (Corin & Ari Wagen, Ep #1)

2 hr 9 min

In my first (real) podcast episode, I talk with Corin and Ari Wagen, two brothers who I met through my writing. They are building something super cool: a molecular simulation company called Rowan (which recently got into the Nat Friedman AI grant program). We discuss neural network potentials (NNP’s), whether dynamics are useful at all, the role of computational chemistry in drug design, what the future of the field looks like for molecular simulation, and a lot more. If you work in molecular simulation, I recommend trying out their tool at rowansci.com. I’m not a chemist and cannot vouch for the tool personally, but I can vouch for how much I’d trust Corin and Ari to build something useful. Not a paid sponsorship, not anything I have an investment in, etc, etc, I just genuinely want their startup to succeed. If you're confused by this episode, check out the 'Jargon Explanation' on the Substack post: https://www.owlposting.com/i/152329408/jargon-explanation Transcript of this episode (contains links to all referenced organizations and papers) My Twitter My Substack (you should subscribe!) Timestamps: 00:00 Introduction 01:19 Divide between classical and quantum simulation 03:48 What are NNP's actually learning? 06:02 What will NNP's fail on? 08:08 Short range and long range interactions in NNP's 10:23 Emergent behavior in NNP's 16:58 Enhanced sampling 18:16 Cultural distinctions in NNP's for life-sciences and material sciences 21:13 Gap between simulation and real-life 36:18 Benchmarking in NNP's 41:49 Is molecular dynamics actually useful? 53:14 Solvent effects 55:17 Quantum effects in large biomolecules 57:03 The legacy of DESRES and Anton 01:02:27 Unique value add of simulation data 01:06:34 NNP's in material science 01:13:57 The road to building NNP's 01:21:13 Building the SolidWorks of molecular simulation 01:30:05 Simulation workflows 01:41:06 The role of computational chemistry 01:44:06 The future of NNP's 01:51:23 Selling to scientists 02:01:41 What would yo...

–

0 ratings from members

5
4
3
2
1

Rate this podcast

Log in to rate and review the shows you listen to.

No reviews yet — be the first member to rate "Owl Posting".

This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.

Keep listening

Discover more podcasts like this.

Up next

  1. Nothing queued. Use + Queue on any episode to line it up.

0:00 0:00